One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway.

SparkCures ID 120
Developed By Merck Sharp & Dohme Corp.
Brand Name Keytruda®
Generic Name Pembrolizumab
Additional Names MK-3475
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.